Trial · NCT03221426
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms | Pembrolizumab + XP/FP | 44.4 | 95% Confidence Interval 33.0 to 69.8 | Months | |
| Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms | Placebo + XP/FP | 25.7 | 95% Confidence Interval 20.8 to 36.5 | Months | |
| Pathological Complete Response (pathCR) Rate - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms | Pembrolizumab + XP/FP | 13.4 | 95% Confidence Interval 10.3 to 17.2 | Percentage of Participants | |
| Pathological Complete Response (pathCR) Rate - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms | Placebo + XP/FP | 2.0 | 95% Confidence Interval 0.9 to 3.9 | Percentage of Participants | |
| Overall Survival (OS) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms | Pembrolizumab + XP/FP | 71.8 | 95% Confidence Interval 52.5 to NA | Months | |
| Overall Survival (OS) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms | Placebo + XP/FP | 55.7 | 95% Confidence Interval 41.7 to NA | Months | |
| Number of Participants Who Experienced One or More Adverse Events (AEs) - Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Pembrolizumab + FLOT Cohort | 99 | Participants | ||
| Number of Participants Who Experienced One or More Adverse Events (AEs) - Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Placebo + FLOT Cohort | 103 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE - Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Pembrolizumab + FLOT Cohort | 37 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE - Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Placebo + FLOT Cohort | 26 | Participants | ||
Number of Participants Who Experienced One or More Adverse Events (AEs) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Pembrolizumab + XP/FP | 396 | Participants | ||
Number of Participants Who Experienced One or More Adverse Events (AEs) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Placebo + XP/FP | 398 | Participants | ||
Number of Participants Who Experienced One or More Adverse Events (AEs) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Pembrolizumab + XP/FP and Pembrolizumab + FLOT Cohort Combined | 495 | Participants | ||
Number of Participants Who Experienced One or More Adverse Events (AEs) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Placebo + XP/FP and Placebo + FLOT Cohort Combined | 501 | Participants | ||
Number of Participants Who Discontinued Study Treatment Due to an AE - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Pembrolizumab + XP/FP | 123 | Participants | ||
Number of Participants Who Discontinued Study Treatment Due to an AE - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Placebo + XP/FP | 103 | Participants | ||
Number of Participants Who Discontinued Study Treatment Due to an AE - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Pembrolizumab + XP/FP and Pembrolizumab + FLOT Cohort Combined | 160 | Participants | ||
Number of Participants Who Discontinued Study Treatment Due to an AE - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms Separately and in Combination With the Pembrolizumab+FLOT and Placebo+FLOT Cohorts | Placebo+ XP/FP and Placebo + FLOT Cohort Combined | 129 | Participants | ||
| Disease-free Survival (DFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms | Pembrolizumab + XP/FP | 66.1 | 95% Confidence Interval 44.9 to NA | Months | |
| Disease-free Survival (DFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms | Placebo + XP/FP | 44.2 | 95% Confidence Interval 27.6 to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03221426/results